Table 1 Patient, donor, and transplant characteristics according to conditioning regimen for all patients.

From: Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT

 

FluTBI (n = 137)

FluTreo (n = 617)

P

Median patient age, years (range)

53.7 (40.1–70.7)

60.7 (40.1–77.5)

<0.0001

Karnofsky performance score

  <90%

27 (20.1%)

133 (22.2%)

0.60

  ≥90%

107 (79.9%)

465 (77.8%)

 

  Missing

3

19

 

Diagnosis

  De novo AML

116 (84.7%)

469 (76%)

0.028

  Secondary AML

21 (15.3%)

148 (24%)

 

Cytogenetic risk group

  Good

4 (3.7%)

15 (3.4%)

0.074

  Intermediate

75 (70.1%)

256 (58.9%)

 

  Poor

28 (26.2%)

164 (37.7%)

 

  NA/failed

30

182

 

  Not adverse

109 (79.6%)

453 (73.4%)

0.14

  Adverse

28 (20.4%)

164 (26.6%)

 

Median interval from diagnosis to HSCT, months (range)

3.8 (1.8–16.2)

4.7 (1.7–22.9)

<0.0001

Median year of HSCT (range)

2014 (2009–2019)

2016 (2009–2019)

<0.0001

MRD status pre-transplant

  MRD negative

31 (64.6%)

143 (59.8%)

0.54

  MRD positive

17 (35.4%)

96 (40.2%)

 

  Missing

89

378

 

Donor

  Matched sibling

88 (64.2%)

224 (36.3%)

<0.0001

  10/10 HLA matched unrelated

49 (35.8%)

393 (63.7%)

 

Patient sex

  Male

84 (61.3%)

329 (53.3%)

0.089

  Female

53 (38.7%)

288 (46.7%)

 

Donor/patient sex

  Female/male

26 (19%)

107 (17.4%)

0.66

  Other combinations

111 (81%)

508 (82.6%)

 

  Missing

0

2

 

Donor/patient CMV status

  Donor negative/patient negative

34 (26.0%)

109 (17.9%)

0.11

  Donor positive/patient negative

11 (8.4%)

37 (6.1%)

 

  Donor negative/patient positive

30 (22.9%)

155 (25.6%)

 

  Donor positive/patient positive

56 (42.7%)

307 (50.5%)

 

  Missing

6

9

 

TBI fractions

 

NA

 

  4 × 2 Gy

40 (29.2%)

  

  2 × 4 Gy

16 (11.7%)

  

  unknown

81 (59.1%)

  

Treosulfan dose

NA

  

  3 × 10 g/m2

 

167 (27.1%)

 

  3 × 12 g/m2

 

122 (19.8%)

 

  3 × 14 g/m2

 

328 (53.2%)

 

In vivo T-cell depletion

  No

74 (54%)

202 (32.7%)

<0.0001

  ATG

63 (46%)

415 (67.3%)

 

GvHD prevention

  Cyclosporin A + MTX

117 (85.4%)

425 (68.9%)

0.0003

  Cyclosporin A + MMF

10 (7.3%)

124 (20.1%)

 

  Other

10 (7.3%)

68 (11.0%)

 

Median follow-up, months [95% CI]

45.88 [35.83–56.96]

26.92 [24.19–31.03]

0.033

  1. HLA human leukocyte antigen, CMV cytomegalovirus, TBI total body irradiation, ATG anti-thymocyte globulin, MTX methotrexate, MMF mycophenolate mofetil, CI confidence interval, NA not applicable.
Back to article page